Randomized controlled trial evaluating the clinical benefit of montelukast for treating spring seasonal allergic rhinitis (Q44325666)

2 December 2017

title

Randomized controlled trial evaluating the clinical benefit of montelukast for treating spring seasonal allergic rhinitis (English)

1 reference

randomized controlled trial

2 December 2017

main subject

1 reference

Janet van Adelsberg

1

1 reference

2 December 2017

George Philip

2

1 reference

2 December 2017

Craig F LaForce

3

1 reference

2 December 2017

Steven F Weinstein

4

1 reference

2 December 2017

Joris Menten

5

1 reference

2 December 2017

Marie-Pierre Malice

6

1 reference

2 December 2017

Theodore F Reiss

7

1 reference

2 December 2017

Montelukast Spring Rhinitis Investigator Group

8

1 reference

2 December 2017

publication date

1 February 2003

1 reference

Annals of Allergy, Asthma & Immunology

2 December 2017

published in

1 reference

2 December 2017

volume

90

1 reference

2 December 2017

issue

2

1 reference

2 December 2017

page(s)

214-222

1 reference

Allergic rhinobronchitis: the asthma-allergic rhinitis link

2 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962144-8

7 January 2021

Role for cysteinyl leukotriene receptor antagonist therapy in asthma and their potential role in allergic rhinitis based on the concept of "one linked airway disease".

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962144-8

7 January 2021

Allergic rhinitis and its impact on asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962144-8

7 January 2021

American Thoracic Society Workshop. Immunobiology of asthma and rhinitis. Pathogenic factors and therapeutic options

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962144-8

7 January 2021

Release of leukotrienes in patients with bronchial asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962144-8

7 January 2021

Leukotriene C4 release in upper respiratory mucosa during natural exposure to ragweed in ragweed-sensitive children

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962144-8

7 January 2021

Immediate and late inflammatory responses to ragweed antigen challenge of the peripheral airways in allergic asthmatics. Cellular, mediator, and permeability changes

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962144-8

7 January 2021

Peptide Leukotriene Release after Antigen Challenge in Patients Sensitive to Ragweed

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962144-8

7 January 2021

Behavior and clinical relevance of histamine and leukotrienes C4 and B4 in grass pollen-induced rhinitis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962144-8

7 January 2021

Leukotriene antagonists and synthesis inhibitors: new directions in asthma therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962144-8

7 January 2021

Leukotriene E4 and granulocytic infiltration into asthmatic airways

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962144-8

7 January 2021

Montelukast, a once-daily leukotriene receptor antagonist, in the treatment of chronic asthma: a multicenter, randomized, double-blind trial. Montelukast Clinical Research Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962144-8

7 January 2021

Montelukast for chronic asthma in 6- to 14-year-old children: a randomized, double-blind trial. Pediatric Montelukast Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962144-8

7 January 2021

Montelukast, a leukotriene receptor antagonist, for the treatment of persistent asthma in children aged 2 to 5 years

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962144-8

7 January 2021

Montelukast for treating seasonal allergic rhinitis: a randomized, double-blind, placebo-controlled trial performed in the spring

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962144-8

7 January 2021

Concomitant montelukast and loratadine as treatment for seasonal allergic rhinitis: a randomized, placebo-controlled clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962144-8

7 January 2021

Development and testing of a new measure of health status for clinical trials in rhinoconjunctivitis.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962144-8

7 January 2021

Measuring health-related quality of life in rhinitis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962144-8

7 January 2021

Quality of life in patients with allergic rhinitis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962144-8

7 January 2021

Efficacy and tolerability of montelukast alone or in combination with loratadine in seasonal allergic rhinitis: a multicenter, randomized, double-blind, placebo-controlled trial performed in the fall

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962144-8

7 January 2021

Hypodense eosinophils in allergic rhinitis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962144-8

7 January 2021

Montelukast reduces airway eosinophilic inflammation in asthma: a randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962144-8

7 January 2021

Montelukast, a leukotriene receptor antagonist, reduces the concentration of leukotrienes in the respiratory tract of children with persistent asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962144-8

7 January 2021

Loratadine. A reappraisal of its pharmacological properties and therapeutic use in allergic disorders

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962144-8

7 January 2021

Interpreting atmospheric pollen counts for use in clinical allergy: allergic symptomology

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962144-8

7 January 2021

The impact of allergic rhinitis on bronchial asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962144-8

7 January 2021

One airway, one disease

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962144-8

7 January 2021

Co-existence of asthma and allergic rhinitis: a 23-year follow-up study of college students

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962144-8

7 January 2021

Leukotrienes in rhinitis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962144-8

7 January 2021

A comparison of once daily fexofenadine versus the combination of montelukast plus loratadine on domiciliary nasal peak flow and symptoms in seasonal allergic rhinitis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962144-8

7 January 2021

10.1016/S1081-1206(10)62144-8

Identifiers

DOI

1 reference

2 December 2017

1 reference